Daptomycin: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
===Pharmacokinetics and Pharmacodynamics=== |
===Pharmacokinetics and Pharmacodynamics=== |
||
| ⚫ | |||
*Distributes well into soft tissues and musculoskeletal system, as well as urine |
*Distributes well into soft tissues and musculoskeletal system, as well as urine |
||
**Poor CNS penetration[[CiteRef::piva2019da]] |
**Poor CNS penetration[[CiteRef::piva2019da]] |
||
**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia |
**Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia |
||
| ⚫ | |||
*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC |
|||
[[Category:Cyclic lipopeptides]] |
[[Category:Cyclic lipopeptides]] |
||
Revision as of 10:15, 28 September 2020
Background
- Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria
Mechanism of Action
- Mechanism of action is to depolarize the cell membrane
Pharmacokinetics and Pharmacodynamics
- Distributes well into soft tissues and musculoskeletal system, as well as urine
- Poor CNS penetration1
- Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia
- Bactericidal
- Concentration-dependent, best predicted by AUC24:MIC
References
- ^ S. Piva, Antonello Di Paolo, Laura Galeotti, Francesco Ceccherini, Francesco Cordoni, Liana Signorini, Tommaso Togni, Amedeo De Nicolò, Frank A. Rasulo, Nazzareno Fagoni, N. Latronico, Antonio D’Avolio. Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. Neurocritical Care. 2019;31(1):116-124. doi:10.1007/s12028-018-0657-y.
